for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Avita Medical Ltd

AVH.AX

Latest Trade

0.70AUD

Change

-0.01(-1.41%)

Volume

3,545,785

Today's Range

0.69

 - 

0.71

52 Week Range

0.07

 - 

0.73

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
0.71
Open
0.70
Volume
3,545,785
3M AVG Volume
175.03
Today's High
0.71
Today's Low
0.69
52 Week High
0.73
52 Week Low
0.07
Shares Out (MIL)
1,871.30
Market Cap (MIL)
1,320.38
Forward P/E
-35.25
Dividend (Yield %)
--

Next Event

Avita Medical Ltd Annual Shareholders Meeting

Latest Developments

更多

Avita Medical Announces Listing On Nasdaq

Avita Medical Receives U.S. FDA Investigational Device Exemption Approval Of Study Evaluating Recell System

Avita Medical Posts FY Loss For Period Attributable $34.6 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Avita Medical Ltd

Avita Medical Limited is a medical technology company. The principal activities of the Company are the commercialization of its regenerative product. The Company has three segments: the Asia Pacific region; the Americas, including Canada, and the Europe, Middle East and Africa (EMEA) region. It develops and distributes regenerative products for the treatment of a range of wounds, scars and skin defects. Its collection and application technology provides treatment solutions derived from the regenerative properties of a patient's own skin. The Company's product, ReCell, is used in the treatment of a range of burns, plastic, reconstructive and cosmetic procedures. Its technology, Regenerative Epithelial Suspension (RES), is an autologous suspension composed of the cells and wound-healing factors necessary to regenerate natural skin. The Company also offers ReGenerCell, which is used for the treatment of wounds, and ReNovaCell, which is used for the treatment of pigmentation.

Industry

Biotechnology & Drugs

Contact Info

28159 Avenue Stanford Ste 220

+44.20.89479804

http://www.avitamedical.com/

Executive Leadership

Lou Panaccio

Chairman of the Board

Michael S. Perry

Chief Executive Officer, Director

Tim Rooney

Interim Chief Financial Officer, Chief Administrative Officer

Troy A. Barring

Chief Operating Officer

Andrew Quick

Senior Vice President - Clinical Development

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, AUD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (AUD)

2017

-0.015

2018

-0.018

2019

-0.027

2020(E)

-0.020
Price To Earnings (TTM)
--
Price To Sales (TTM)
161.77
Price To Book (MRQ)
44.29
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.18
LT Debt To Equity (MRQ)
0.18
Return on Investment (TTM)
-141.81
Return on Equity (TTM)
-117.68

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up